Posttraumatic Stress Disorder Severity-related Accelerated Aging, Hippocampal Volume, and CLDN5 DNA Methylation.

Abstract

Objective: The claudin-5 ( CLDN5) gene is critical for blood-brain barrier integrity and may link traumatic stress, accelerated aging, and neurological disease. Building on prior research showing associations between trauma exposure and PTSD with CLDN5 DNA methylation (DNAm), we tested whether candidate CLDN5 DNAm loci were associated with advanced epigenetic aging in blood and brain tissue and with hippocampal volume.

Methods: A total of 1302 trauma-exposed individuals (M age = 44.23, SD = 13.71; 76% males) underwent psychiatric diagnostic interviews and blood draws for obtaining epi/genetic information; 473 underwent magnetic resonance imaging of the brain. Data from 109 PTSD brain bank decedents with DNAm from ventromedial prefrontal cortex (vmPFC) were also examined (M age-at-death = 45.20, SD = 14.21; 62% males).

Results: All candidate loci were associated with metrics of epigenetic age in blood ( p-adj range: .0396 to 4.5e-05), and these associations largely extended to postmortem vmPFC. There was an indirect association between PTSD severity and CLDN5 DNAm in blood at cg21872764 through GrimAge residuals (indirect β = 0.033, p = .040) that was diminished when the direct PTSD association was modeled. The CLDN5 probe cg17411190 in blood was negatively related to left and right hippocampal volume ( p-adj = .042) and with volume of multiple hippocampal substructures. The association between PTSD severity and hippocampal volume was indirect through blood DNAm at cg17411190 (indirect β = -0.011, p = .045).

Conclusions: PTSD severity-related accelerated aging may be associated with altered CLDN5 DNAm, which may signal neurodegeneration, such as reduced hippocampal volume. CLDN5 DNAm in blood may serve as a useful proxy for brain CLDN5 DNAm. Given that prior environmental enrichment and antidepressant studies show initial efficacy in altering CLDN5 expression, future studies could evaluate if PTSD treatment alters CLDN5 epigenetics and reduces risk for neurodegeneration.